Proteostasis Therapeutics (PTI) Makes Several Exec. Appointments; Includes CFO, Board Member
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Proteostasis Therapeutics, Inc. (Nasdaq: PT) announced the appointment of James M. DeTore as chief financial officer, Geoffrey S. Gilmartin, M.D. as chief development officer, Marija Zecevic, Ph.D. as vice president of business development, and Eric B. Rabinowitz as a new member of the company’s board of directors.
“We couldn’t be more pleased to welcome Jim, Geoffrey and Marija as we expand our leadership team,” said Meenu Chhabra, president and chief executive officer of Proteostasis Therapeutics. “Jim’s breadth and depth of experience with small-and large-scale biotech and pharmaceutical companies will be invaluable as we put into place the financial and operational infrastructure necessary to advance our clinical program. Likewise, Geoffrey’s extensive experience leading clinical development for companies such as AstraZeneca and Vertex Pharmaceuticals will help shape our regulatory and commercial strategies moving forward. Marija’s track record in driving business development initiatives will further support the execution of value-generating strategic transactions from our DRT platform.”
Mr. DeTore joins the company from bluebird bio, Inc., where he served as chief financial officer from 2014 through 2016, leading the company’s financings and investor relations strategies, and helping to raise over $720 million in capital. Prior to bluebird, he served for eight years in positions of increasing responsibility at Ironwood Pharmaceuticals, Inc., culminating as vice president of corporate finance and prior to that as the corporate controller at Ironwood’s predecessor company, Microbia, Inc. Mr. DeTore received his Master of Business Administration and bachelor’s degree in finance from Northeastern University.
Dr. Gilmartin joins Proteostasis Therapeutics from AstraZeneca, where he most recently served as senior medical lead for global medicines development, including the company’s benralizumab Phase 3 program in severe asthma. Dr. Gilmartin joined AstraZeneca in January 2014. Prior to his time there, he held positions of increasing responsibility at Vertex Pharmaceuticals including serving as medical lead for the KalydecoTM (ivacaftor) clinical development program, as well as spearheading the initiation of Phase 3 trials to support label expansion studies for the drug. Dr. Gilmartin joined Vertex Pharmaceuticals in January 2011. In addition to his leadership in the life sciences industry, Dr. Gilmartin is an attending physician for the intensive care unit at Beth Israel Deaconess Medical Center and formerly served as director of the BIDMC Sleep Disorders Center and on the pulmonary leadership team. Dr. Gilmartin completed his undergraduate degree at Dartmouth College and received his M.D. from Brown University School of Medicine and his Master of Medical Science in clinical research from Harvard Medical School.
Dr. Zecevic has collaborated with Proteostasis Therapeutics on multiple projects since July 2014. Dr. Zecevic was the founder and managing director at Zebra Ventures, a consulting firm based in Italy where she led licensing discussions with top 10 pharma companies on behalf of the firm’s clients among which was the Italian Cystic Fibrosis Research Foundation. Prior to that, Dr. Zecevic held several positions of increasing responsibility at Bioxell, a Roche spin-off where she supported all licensing and fundraising activities from top tier European and U.S. venture capital firms that culminated in an IPO on the Swiss Stock Exchange in 2006. Dr. Zecevic received her Ph.D. in physiology from the University of Zurich and a Master of Science in healthcare management, economics and policy from the University Bocconi in Milan.
In addition to the appointments of Mr. DeTore, Dr. Gilmartin and Dr. Zecevic, Proteostasis Therapeutics has appointed Eric B. Rabinowitz to its board of directors. Conor Walshe will be stepping down. Mr. Rabinowitz joins Proteostasis Therapeutics from Perrigo Company, PLC where he is the vice president of global corporate development and leads the team in devising Perrigo’s strategy and identifying and executing inorganic growth opportunities to achieve its long-term objectives. Prior to joining Perrigo in August 2014, Mr. Rabinowitz held several positions of increasing responsibility over an 11 year career in investment banking. Mr. Rabinowitz earned his undergraduate degree from the University of Florida, Fischer School of Accounting and a Master of Business Administration from The University of Chicago Booth School of Business.
“We are excited by our continued growth in 2016,” said Chhabra. “The appointment of Mr. Rabinowitz to our board brings the critical knowledge and experience to help drive progress and strategic direction for the company. We look forward to announcing additional clinical updates in the coming weeks.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- Wells Fargo (WFC) Changes By-Laws to Require Separation of Chairman and CEO Roles
- Skyline Medical (SKLN) Appoints New CEO, Board Member
Create E-mail Alert Related CategoriesManagement Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!